XXXX versus bone scintigraphy in the detection of bony metastases of @entity521 .

@entity1 @entity75 @entity7990 @entity79 @entity521 @entity13098
@entity79 ( @entity79 ) is widely utilized for the assessment of bone metastases (BMs) of @entity521 ( @entity521 ). Since @entity13098 scintigraphy (PS) has been used to image @entity521 with high sensitivity, we compared the sensitivity and specificity of PS with that of @entity79 for the detection of BMs of @entity521 . Nine @entity1 with @entity521 underwent both PS and @entity79 for staging and/or restaging of their disease. The sensitivity and specificity of both imaging approaches were compared based on the findings of histopathology, other conventional imaging methods and subsequent clinical follow-up. In five of the nine @entity1 , both PS and @entity79 were negative for BMs. Radiographic bone surveys (RBSs) were also negative in these @entity1 , except in one who showed a suspicious @entity75 , but a computed tomography-guided biopsy failed to show evidence of disease. These @entity1 remained without clinical evidence of BMs after a median duration of more than 15 months (range, 6-19 months). In three of four remaining @entity1 , both PS and @entity79 were positive for BMs, whilst only PS was positive in one @entity1 . Overall, PS showed a greater number of BMs (30 vs. 7) with greater conspicuity compared with @entity79 . The initial experience comparing @entity79 with PS suggests that PS may provide a better assessment of the extent of BMs of @entity521 , and that it may be useful as an adjunct to @entity79 at institutions in which 131I- or 123I- @entity7990 is not available, particularly if @entity79 is negative. In @entity1 with similarly positive @entity79 , PS might still provide unique prognostic information beyond that provided by @entity79 . Further studies are therefore warranted.
